التفاصيل البيبلوغرافية
| العنوان: |
Development and evaluation of a low cost IgG ELISA test based in RBD protein for COVID-19. |
| المؤلفون: |
Villafañe, Luciana1 (AUTHOR) villafane.luciana@inta.gob.ar, Vaulet, Lucía Gallo1,2,3 (AUTHOR), Viere, Florencia M.4 (AUTHOR), Klepp, Laura I.1 (AUTHOR) klepp.laura@inta.gob.ar, Forrellad, Marina A.1 (AUTHOR) forrellad.marina@inta.gob.ar, Bigi, María M.5 (AUTHOR) mbigi@conicet.gov.ar, Romano, María I.1 (AUTHOR) romano.mariaisabel@inta.gob.ar, Magistrelli, Giovanni6 (AUTHOR) giovanni.magistrelli@lightchainbio.com, Fermepin, Marcelo Rodríguez2,3 (AUTHOR) mrfchlam@ffyb.uba.ar, Bigi, Fabiana1 (AUTHOR) bigi.fabiana@inta.gob.ar |
| المصدر: |
Journal of Immunological Methods. Jan2022, Vol. 500, pN.PAG-N.PAG. 1p. |
| مصطلحات موضوعية: |
*COVID-19, *COVID-19 pandemic, *VACCINE effectiveness, *SERODIAGNOSIS, *SARS-CoV-2 |
| مستخلص: |
Serology tests for SARS-CoV-2 have proven to be important tools to fight against the COVID-19 pandemic. These serological tests can be used in low-income and remote areas for patient contact tracing, epidemiologic studies and vaccine efficacy evaluations. In this study, we used a semi-stable mammalian episomal expression system to produce high quantities of the receptor-binding domain-RBD of SARS-CoV-2 in a simple and very economical way. The recombinant antigen was tested in an in-house IgG ELISA for COVID-19 with a panel of human sera. A performance comparison of this serology test with a commercial test based on the full-length spike protein showed 100% of concordance between tests. Thus, this serological test can be an attractive and inexpensive option in scenarios of limited resources to face the COVID-19 pandemic. • Highly efficient expression of RBD domain from episomal plasmid in mammalian cells. • Low cost RBD-ELISA yielded results 100% concordant to Spike-ELISA. • All sera from vaccinated people recognized RBD protein in the in-house ELISA. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
